BEAT - NASDAQ
HeartBeam, Inc.
$1.47
+8.1%HeartBeam, Inc., a medical technology company, primarily focuses on telemedicine solutions for the detection and monitoring of cardiac disease outside a healthcare facility setting. The company also focuses on providing diagnostic data to physicians with care management of patients with cardiovascular disease. Its telehealth product comprises a credit card sized electrocardiogram machine and a cloud-based diagnostic software system to address the rapidly growing field of remote patient monitoring. The company was incorporated in 2015 and is headquartered in Santa Clara, California.
At a Glance
Live Snapshotbeat
Cash at End of Period
Last Annual Value
4.44M
3-Year CAGR
7%
5-Year CAGR
184%
10-Year CAGR
-14%
HeartBeam, Inc. Competitors Analysis of Cash at End of Period
| Company | Cash at End of Period | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
HeartBeam, Inc. NASDAQ:BEAT | 4.44M | -35.1% | -19.6% | -15.2% | |
 Equillium, Inc. NASDAQ:EQ | 30.28M | 9.3% | -9.7% | N/A | |
 Spruce Biosciences, Inc. NASDAQ:SPRB | 48.94M | -20.2% | 2.6% | N/A | |
 Cue Biopharma, Inc. NASDAQ:CUE | 27.29M | -17.5% | -15.8% | 6.2% | |
 TELA Bio, Inc. NASDAQ:TELA | 51.09M | 2.8% | 3.1% | N/A | |
 Pulmonx Corporation NASDAQ:LUNG | 70.01M | -5.8% | -14.0% | N/A | |
 MediciNova, Inc. NASDAQ:MNOV | 30.81M | -15.5% | -15.5% | 2.5% | |
 NRx Pharmaceuticals, Inc. NASDAQ:NRXP | 7.80M | 19.3% | -22.3% | N/A | |
 MiNK Therapeutics, Inc. NASDAQ:INKT | 13.36B | 1483.1% | 221.5% | N/A | |
 Werewolf Therapeutics, Inc. NASDAQ:HOWL | 57.95M | -28.0% | -18.3% | N/A | |
 OS Therapies Incorporated NYSE:OSTX | 5.53M | 421.7% | 132.9% | N/A |
HeartBeam, Inc. Fair Value Envelope
Related Guides
Continue your BEAT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.